PubRank

Peter M A Calverley

Author PubWeight™ 109.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2007 8.06
2 Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014 6.29
3 Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 6.17
4 Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011 5.69
5 Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010 5.17
6 Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009 4.40
7 Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009 3.93
8 Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004 3.77
9 Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008 3.70
10 Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2012 3.44
11 Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012 2.52
12 Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013 2.42
13 Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009 2.31
14 Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009 2.20
15 The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med 2004 2.00
16 A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2011 1.98
17 Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc 2015 1.72
18 Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013 1.66
19 Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 2005 1.54
20 Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res 2011 1.52
21 The Association Between Heroin Inhalation and Early Onset Emphysema. Chest 2015 1.46
22 Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013 1.41
23 Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med 2010 1.33
24 Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 2013 1.31
25 Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med 2010 1.30
26 Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2011 1.28
27 Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2011 1.23
28 Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014 1.20
29 Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 1.16
30 Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007 1.14
31 Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulm Med 2013 1.14
32 Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013 1.12
33 Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med 2011 1.11
34 Factors associated with change in exacerbation frequency in COPD. Respir Res 2013 1.08
35 COPD performance measures: missing opportunities for improving care. Chest 2010 1.05
36 The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2012 1.03
37 α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010 1.02
38 The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD 2008 0.99
39 Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med 2014 0.93
40 The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit? Thorax 2012 0.91
41 Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Ann Nutr Metab 2013 0.91
42 Spirometry in chronic obstructive pulmonary disease. BMJ 2006 0.90
43 Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene. Am J Respir Crit Care Med 2010 0.89
44 The effect of posture on asynchronous chest wall movement in COPD. J Appl Physiol (1985) 2013 0.86
45 The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. Respir Med 2006 0.86
46 Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data. Respir Med 2008 0.86
47 Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015 0.85
48 Pathological networking: a new approach to understanding COPD. Thorax 2007 0.85
49 A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007 0.82
50 Measuring habitual physical activity in adults with cystic fibrosis. Respir Med 2013 0.80
51 Chronic airflow limitation in a rural Indian population: etiology and relationship to body mass index. Int J Chron Obstruct Pulmon Dis 2011 0.79
52 Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2014 0.78
53 Lung function changes following methacholine inhalation in COPD. Respir Med 2008 0.77
54 Inhaled glucocorticoids and COPD exacerbations. N Engl J Med 2015 0.77
55 Evaluating the role of inflammation in chronic airways disease: the ERICA study. COPD 2014 0.77
56 A study of patient attitudes in the United Kingdom toward ventilatory support in chronic obstructive pulmonary disease. J Palliat Med 2009 0.76
57 UPLIFTing care for chronic obstructive pulmonary disease. Lancet 2009 0.75
58 Response. Chest 2014 0.75
59 Taking the long view of COPD care. Prim Care Respir J 2011 0.75